Bambusa Therapeutics, Inc. (BBTX) company profile
BBTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.00+0.00 (0.00%)
Close on Nov 3, 2026Market cap –P/E –Yield –
About Bambusa Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Bambusa Therapeutics, Inc. is listed on Nasdaq under the ticker BBTX, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Bambusa Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 22 Boston Wharf Road, Floor 7
- Phone
- (617) 848-6188
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BBTX
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2026
- SEC CIK
- 2044950
- FIGI
- BBG01NSJ2K90
- Share class FIGI
- BBG01NSJ2KS9
- EIN
- 99-2083913
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shanshan Xu | See remarks, Director | 7,562,518 |
| Jonathan I. Lieber | Chief Financial Officer | – |
| Minh Quoc Thang Ho | See remarks | – |
| Rajeev M. Shah | Director | – |
| Capital Healthcare Fund LP RA | Director | – |
| Ra Capital Management, L.P. | Director | 1,495,971 |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Peter Kolchinsky | Director | – |
| Helmut Wolfgang Jeggle | Director | 9,264,301 |
| Derek DiRocco | Director | – |
| Howard Liang | Director | – |
| Christian Uwe Foerster | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?